- Conditions
- Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
- Interventions
- Deferoxamine, Deferiprone (L1)
- Drug
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1489–1512
of 17,846
matching trials from the live ClinicalTrials.gov search.
- Conditions
- NSCLC
- Interventions
- EP0031, Platinum chemotherapy, Pemetrexed
- Drug
- Lead sponsor
- Ellipses Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Alzheimer's Disease
- Interventions
- Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
- Drug
- Lead sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
- Industry
- Eligibility
- 50 Years to 88 Years
- Enrollment
- 1,121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 143 more
- Conditions
- Diabetes Complications, Diabetes Mellitus, Type 2
- Interventions
- Telephone Counseling
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alcohol Associated Hepatitis
- Interventions
- INT-787, Placebo
- Drug
- Lead sponsor
- Intercept Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Fresno, California • Palo Alto, California • Sacramento, California + 17 more
- Conditions
- Colorectal Cancer
- Interventions
- folic acid
- Dietary Supplement
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 21 Years to 120 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2009
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Stroke, Healthy
- Interventions
- WIM Robotic Exoskeleton
- Device
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Ruxolitinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Burbank, California + 35 more
- Conditions
- Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
- Interventions
- Urelumab (BMS-663513)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- obinutuzumab, rituximab, chlorambucil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 787 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 5
- States / cities
- San Diego, California • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Vertigo, Vestibular Disease
- Interventions
- Liberatory Maneuver, Placebo maneuver
- Other
- Lead sponsor
- Midwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Downers Grove, Illinois
- Conditions
- Postherpetic Neuralgia
- Interventions
- Civamide Patch
- Drug
- Lead sponsor
- Winston Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Sunrise, Florida • Chicago, Illinois • Ann Arbor, Michigan
- Conditions
- Venous Leg Ulcers
- Interventions
- HP802-247, Vehicle
- Biological
- Lead sponsor
- Healthpoint
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- ZD6474, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 12
- States / cities
- Concord, California • Los Angeles, California • Chicago, Illinois + 9 more
- Conditions
- Fibromyalgia
- Interventions
- Transcutaneous Electrical Nerve Stimulation (TENS) with PT, PT only
- Device · Other
- Lead sponsor
- Kathleen Sluka
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Moline, Illinois • Cedar Rapids, Iowa + 3 more
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer
- Interventions
- proteomic profiling, surface-enhanced laser desorption/ionization-time of flight mass spectrometry, biopsy
- Genetic · Other · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Burbank, California + 80 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- warfarin, placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
- Conditions
- Leukemia, Myeloid, Chronic Phase
- Interventions
- Imatinib mesylate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 476 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 50
- States / cities
- Mobile, Alabama • Berkeley, California • Campbell, California + 35 more
- Conditions
- HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
- Interventions
- ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
- Conditions
- Secondary AML
- Interventions
- CPX-351
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Chronic Hepatitis C
- Interventions
- valopicitabine, Pegylated Interferon Alfa
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 175 participants
- Timeline
- Started 2005
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • San Diego, California • San Mateo, California + 16 more
- Conditions
- Hemophilia A, Severe Hemophilia A
- Interventions
- rVIII-SingleChain
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Male only
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 9
- States / cities
- San Diego, California • Aurora, Colorado • Hartford, Connecticut + 6 more